NFE2L2 and diabetes mellitus: The results demonstrated that the decreased expression of Nrf2 and its downstream antioxidant genes in diabetes was reversed by the treatment with EMPA, indicating that the antioxidant effects of EMPA are largely through activating Nrf2 signaling.